

Provisional Application for Patent Cover Sheet					
This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c)					
Inventor(s)					
Inventor 1					Remove
Given Name	Middle Name	Family Name	City	State	Country
Jeffrey	B	Etter	Boulder	CO	US
All Inventors Must Be Listed – Additional Inventor Information blocks may be generated within this form by selecting the Add button.					Add
Title of Invention		ORAL AZACITIDINE AND EFFICACIOUS ESCALATED DOSAGE FORMS			
Attorney Docket Number (if applicable)		298068-00042			
Correspondence Address					
Direct all correspondence to (select one):					
☒ The address corresponding to Customer Number			☐ Firm or Individual Name		
Customer Number			03705		

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.	
☒ No.	
☐ Yes, the name of the U.S. Government agency and the Government contract number are:	

Entity Status

Applicant claims small entity status under 37 CFR 1.27


- ☐ Yes, applicant qualifies for small entity status under 37 CFR 1.27
- ☒ No

Warning

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

Signature

Please see 37 CFR 1.4(d) for the form of the signature.

Signature				Date (YYYY-MM-DD)	May 15, 2008
First Name	Patrick	Last Name	Higgins	Registration Number (If appropriate)	39709

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. This form can only be used when in conjunction with EFS-Web. If this form is mailed to the USPTO, it may cause delays in handling the provisional application.

**A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics,
and Pharmacodynamics of Oral Azacitidine in Subjects with Melodysplastic Syndromes
(MDS) or Acute Myelogenous Leukemia (AML)**

B.S. Skikne¹, M.R. Ward², A. Nassar², G. Garcia-Manero³

**University of Kansas Medical Center, Kansas City, KS¹, Celgene Corporation, Summit,
NJ², University of Texas MD Anderson Cancer Center, Houston, TX³**

ORAL AZACITIDINE AND EFFICACIOUS ESCALATED DOSAGE FORMS

Jeffrey B. Etter
1318 Deer Trail Rd.
5 Boulder, CO 80302

- The present invention is drawn toward azacitidine compositions and dosage forms thereof for oral administration which, for example, yield continuous low-dose drug release profiles upon oral administration and thereby result in improved efficacy, safety, pharmacokinetics, and pharmacodynamics. Oral dosages described herein are administered, for example, for the treatment of myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML) conditions. Etter, J.B., U.S. Application Ser. No.11/849,958 is incorporated in its entirety by reference. See, for example, the primary examples, and formulation #1 described therein.
- Oral azacitidine dosages (and methods of administration thereof and/or methods of treatment of at least one condition, including but not limited to MDS and AML) of the present invention may range, for example, between about 50 mg/m²/day and about 2,000mg/m²/day, between about 100 mg/m²/day and about 1,000mg/m²/day, between about 100 mg/m²/day and about 500mg/m²/day, between about 120 mg/m²/day and about 250mg/m²/day. Particular dosages, for example, are about 120 mg/m²/day, about 140 mg/m²/day, about 150 mg/m²/day, about 180 mg/m²/day, about 200 mg/m²/day, about 220 mg/m²/day, about 240 mg/m²/day, about 250 mg/m²/day, about 260 mg/m²/day, about 280 mg/m²/day, about 300 mg/m²/day, about 320 mg/m²/day, about 350 mg/m²/day, about 380 mg/m²/day, about 400 mg/m²/day, about 450 mg/m²/day, and about 500 mg/m²/day.
- A phase 1, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in subjects with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML) is described herein. Azacitidine, a cytidine analog, through its effects on DNA metabolism, gene expression, and cell differentiation, has proven beneficial in treatment of MDS and AML. Most notably, prolonged azacitidine therapy recently has been shown to approximately double 2-year survival in higher-risk MDS subjects compared to conventional care. Azacitidine is currently approved for intermittent subcutaneous (SC) and intravenous administration. Development of an oral formulation would provide more convenient dosing, eliminate injection-site reactions, and

allow evaluation of novel, continuous low-dose regimens that may sustain demethylation and improve efficacy. A proprietary formulation of oral azacitidine was shown to be absorbed in a pilot, single-dose study (ASCO 2007). *See, e.g.,* U.S. Application Ser. No.11,849,958.

- 5 **Multicenter, open-label, Phase 1, sequential design, dose-escalation study of oral azacitidine.** The study is designed to evaluate the maximum tolerated dose (MTD), dose limiting toxicities (DLTs), safety, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of increasing doses of orally administered azacitidine in subjects with MDS or AML. Azacitidine was administered SC (75 mg/m²/day x 7 days) during cycle 1, then orally
- 10 starting at 120 mg x 7 days/28 day cycle. Drug levels were measured in plasma and urine, and PD effects including global LINE methylation and gene-specific methylation were assayed.

Results

- 15 Currently, no toxicities have been observed in subjects who have completed both the SC and oral phases of the study at 120 mg. The study continues at the 180 mg dose level. Preliminary PK analysis indicates detectable plasma levels at the 120 mg oral dose. A comparison of plasma PK profiles and PD effects of azacitidine administered at increasing oral doses compared to those of azacitidine administered SC at the approved dose of 75 mg/m²/day for
- 20 all subjects evaluated to date.

Conclusions

Results of oral 5-azacitidine indicate that this formulation is orally bioavailable and safe in subjects with MDS, for example.

25

* * *

EXHIBIT I

- 30 *Attached hereto*, is an Example (image Poster), entitled **A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Melodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)**, intended for presentation at ASCO 2008, on or about May 16, 2008.

35

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.